EZH2 and B-cell non-Hodgkin lymphoma: Another group proposed a new ddPCR assay able to detect and quantify the hot spots mutations of EZH2, STAT6, MYD88, and CCND3 that characterize about 20% of B-cell lymphomas, especially the germinal center DLBCL (GB-DLBCL) and follicular lymphoma (FL) that seem to be associated with resistance to treatment.